The aim of this study was to characterize individual-segment and overall patterns of VH gene usage in adult B-lineage acute lymphoblastic leukemia (ALL). Theoretical values of VH segment usage were calculated with the assumption that all VH segments capable of undergoing rearrangement have an equal probability of selection for recombination. Leukemic clones from 127 patients with adult B-lineage acute leukemias were studied by fingerprinting by means of primers for the framework 1 and joining segments. Clones from early preimmune B cells (245 alleles identified) show a predominance of VH6 family rearrangements and, consequently, do not conform to this hypothesis. However, profiles of VH gene family usage in mature B cells, as investigated in peripheral blood (6 samples), B-cell lymphomas (36 clones) and chronic lymphocytic leukemia (56 clones), are in agreement with this theoretical profile. Sequence analyses of 64 VH clones in adult ALL revealed that the rate of VH usage is proportional to the proximity of the VH gene to the JH locus and that the relationship can be mathematically defined. Except for VH6, no other VH gene is excessively used in adult ALL. VH pseudogenes are rarely used (n = 2), which implies the existence of early mechanisms in the pathway to B-cell maturation to reduce wasteful VH-(DH)-JHrecombination. Finally, similar to early immunoglobulin-H rearrangement patterns in the mouse, B cells of ALL derive from a pool of cells more immature than the cells in chronic lymphoid B-cell malignancies.

Immunoglobulin heavy chain gene rearrangement involves the joining of 1 variable (VH), 1 diversity (D), and 1 joining segment (JH) and precedes light chain gene rearrangement in a hierarchical pattern. This process is essential for the progression of early B cells to maturity and functional antibody assembly.1,2 A total of 123 VHsegments3,4 (depending on haplotype), 26 D segments,4,5 and 9 JH segments5are organized in a telomeric-to-centromeric orientation on chromosome 14 band q32.2 VH segments are classified into 7 families (VH1 through VH7) on the basis of amino acid sequence homology6 (Table1). VH3 is the largest family, followed by VH4 and VH1 (64, 32, and 19 members, respectively), whereas VH2, VH5, and VH6 contain only 4, 2, and 1 member, respectively. The unique VH6 is the most 3′ element and is closest to the D and JH loci.4 

Table 1.

VH gene segments on chromosome 14q32.2

Type of VH gene segmentNo. segments in VH familiesTotal
VH1/VH7VH2VH3VH4VH5VH6
Total germline segments (rows A, B, C) 19 65 32 123 
 (%) (15.4) (3.3) (52.8) (26.0) (1.6) (0.8)  
Rearrangable (rows A + B) 14 27 55 
 (%) (25.5) (7.3) (49.1) (14.5) (1.8) (1.8)  
A) Functional 10 20 42 
 (%) (23.8) (7.1) (47.6) (16.7) (2.4) (2.4)  
 Functional protein equivalent found 19  
 Transcribed mRNA equivalent found — — — — —  
 Other VH with ORF, intact promoter, and RSS — — — —  
B) Pseudogenes with intact promoter and RSS — — 13  
C) Nonrearrangeable pseudogenes — 38 24 — 68 
Type of VH gene segmentNo. segments in VH familiesTotal
VH1/VH7VH2VH3VH4VH5VH6
Total germline segments (rows A, B, C) 19 65 32 123 
 (%) (15.4) (3.3) (52.8) (26.0) (1.6) (0.8)  
Rearrangable (rows A + B) 14 27 55 
 (%) (25.5) (7.3) (49.1) (14.5) (1.8) (1.8)  
A) Functional 10 20 42 
 (%) (23.8) (7.1) (47.6) (16.7) (2.4) (2.4)  
 Functional protein equivalent found 19  
 Transcribed mRNA equivalent found — — — — —  
 Other VH with ORF, intact promoter, and RSS — — — —  
B) Pseudogenes with intact promoter and RSS — — 13  
C) Nonrearrangeable pseudogenes — 38 24 — 68 

Based on Matsuda et al.4 

mRNA indicates messenger RNA; ORF, open-reading frames; RSS, recombination signal sequence.

Only half of all VH genes carry intact recombination signal sequences (RSS), which are important cis-acting elements required for VH-(D)-JHrecombination.7 The remaining are consequently “nonfunctional,” as are VH genes with point mutations resulting in frame shifts and stop codons (28 VH genes). Forty-two VH segments either are known to be functional (39 segments) or have been found transcribed (1 segment) or with open-reading frames (2 genes) but not yet in a rearranged form. A putative requirement for recombination is low-level tissue-specific transcription8-10 from VH promoters (one per segment), coordinated with chromatin accessibility to recombination enzymes,11 in both human and murine B cells.12-15 When these factors are taken into account, 55 out of 123 (44.7%) VH segments are capable of undergoing rearrangement, but only 42 of 55 (76%) are potentially functional (Table 1). Under the assumption that 2 of 3 recombinations will be out of frame, the probability that any rearrangement will be functional is 1/3 × (42/55) = 0.25 or 25%.

The final immunoglobulin repertoire seen in B cells will reflect diversity generated through VH-(D)-JHrecombinations, and any positive or negative selections throughout development and maturation, prior to contact with antigens.5 Although it is clear that the repertoire shifts throughout ontogeny and maturation, the early controlling events are not clear. The final repertoire in mature adult B cells are unrestricted and unbiased, as shown by studies in peripheral blood, spleen B cells, or tonsil B cells.16-21 Many groups have reported that mammalian fetal VH-(D)-JHrepertoires (in liver, spleen, bone marrow, or peripheral blood) are highly restricted, and only a few rearranged VH genes (VH3 or VH5 or VH6) dominate.16,17,22-28 Other researchers disagree.29-31 Murine studies show a consistent overuse of JH-proximal VH segments in fetal22,23,25-27 and adult23,26,27 32 B-cell progenitor cells.

Few studies have been done in adult human preimmune B cells. Immature splenic B cells, but not mature peripheral B cells, have been shown to exhibit fetal-like VH6 overusage.17In post– allogeneic marrow transplantation patients, it has been shown that the B cells repopulating the periphery early (at 2 to 5 months) have overexpression of VH6 and a pattern of VH usage similar to those of neonatal and infant blood cells. By 6 to 12 months, the pattern becomes less marked.33 Others studies disagree34 and suggest a limited clonal diversity at 6 to 10 weeks and a normal repertoire by 6 to 9 months. This was supported by a group who showed that VH3 is the predominant family in the periphery at 6 months.35 It has been suggested that B-cell development during reconstitution of the periphery might follow a wavelike shifting pattern.36 

Acute lymphoblastic leukemia (ALL) is a good model for the study of VH-(D)-JH rearrangements, as it allows examination of individual recombination events from clonally expanded pre-immune B-cell populations. Previous work37,38including our own,39 demonstrated essentially normal VH usage profiles in B-lineage ALL in both adults and children, but with a noticeable increase in VH6 usage (between 8.5% and 12%). These studies were carried out on mixed age groups with limited numbers, a situation that restricts firm statistical comparisons.

Here we expand our preliminary study39 and report on the immunoglobulin IGH gene analysis carried out on 127 adult ALL patients (245 alleles) with the use of IGH fingerprinting to define the VH gene pattern of rearrangement. Our aim was to investigate the pattern of VH usage in ALL patients, free of antigen-driven selection pressure, and test the hypothesis that preimmune B cells (as in adult B-lineage ALL clones) undergo random, nonbiased, nonrestricted VH segment usage.

Patient and control samples

Bone marrow (BM) specimens from 159 adults (aged 15 to 55) with B-lineage ALL were investigated as part of the UKALL XII adult leukemia trial. Between 1992 and 1999, samples were collected from patients at presentation (147 cases) or first relapse (12 cases). The majority of cases were common ALL (cALL) (93 of 159; 58%) or pre-B ALL (48 of 159; 30%); fewer had null ALL (14 of 159; 9%) or L3 B ALL (4 of 159; 2.5%).40 

Control samples used for comparison consisted of 6 BM (BM1 through BM6) and 6 peripheral blood (PB) (PB1 through PB6) samples from healthy donors, PB from 56 patients with chronic lymphocytic leukemia (CLL), diagnostic biopsies from 36 B-cell lymphoma patients, and BM from 63 childhood ALL patients.

DNA extraction procedures

Where fresh material was available (including all normal BM and PB, approximately 60% of adult B-lineage ALL, and all CLL and B-cell lymphoma samples), mononuclear cell separation, DNA extraction, and qualitative assessment of DNA prior to polymerase chain reaction (PCR) amplification were carried out as previously described.41Where fresh material was not available (about 40% of adult B-lineage ALL), DNA was extracted from archival material (stained or unstained slides) as follows. Slides were washed twice, briefly, with sterile water. Cells were scraped off damp slides into 0.5 mL Dexpat suspension (Biowhittaker, Workingham, Berkshire, United Kingdom) and boiled for 10 minutes in a dry heating block. After this was allowed to cool to room temperature, a suspension was spun in a microfuge for 10 minutes at 4°C. Supernatant was then transferred to a new tube and extracted twice with an equal volume of phenol/chloroform/isopropanol (25:24:1 vol/vol), followed by one chloroform/isopropanol (24:1 vol/vol) extraction. DNA was then recovered by ethanol precipitation. Qualitative assessment of DNA prior to PCR amplification was carried out as before.41 

PCR assay of VH-(D)-JH rearrangement

For material from B-cell lymphoma, CLL, and childhood ALL, assessment of IgH rearrangement (fingerprint analysis) was carried out by PCR as previously described.39 In patients with less than 5 μg DNA total (fewer than 30% of adult ALL patients) the IgH pattern was analyzed by radionucleotide-incorporated PCR.41 In brief, 6 PCR reactions, spiked with the radionucleotide α32P–deoxycytidine triphosphate, were set up per sample, by means of 1 each of 6 sense family-specific (VH1 through VH6) framework 1 primers in combination with an antisense JH primer, as previously described.41 The VH1 forward primer was designed to also amplify VH7 sequences. The B-cell lymphoma samples were assayed with sense family-specific (VH1 through VH6) primers for the leader sequences42 and the JH primer described above. CLL samples were amplified as described for the adult ALL, as were samples from childhood ALL.

Cloning and DNA sequencing

After agarose or polyacrylamide gel separation, the DNA bands were excised and purified through Sephadex G50-medium columns or Jetsorb gel extraction kit (Genomed, Bad Oeynhausen, Germany), respectively. DNA was digested with the restriction enzymes included in the designed primers (HindIII and EcoRI) (Biolabs, Hitchin, Herts, United Kingdom) and then cloned into Bluescript plasmid KS+ (Stratagene, Amsterdam, The Netherlands), and DNA from colonies was prepared by means of the QIAprep Spin Plasmid Kit (Qiagen, Crawley, West Sussex, United Kingdom), following the manufacturer's recommendations. The relevant DNA fragments were sequenced by means of an automated sequencer (ABI PRISM 377, Warrington, Cheshire, United Kingdom) according to the manufacturer's specifications.

Densitometry

Normal BM, normal PB, and a small proportion of adult B-lineage ALL PCR products were quantitated by densitometry. Visible PCR bands on photosensitive films were scanned on an imaging densitometer (Biorad GS-700, Hemel Hempstead, Herts, United Kingdom) and analyzed for optical density (Quantity One version 4.0).

Sequence analysis

The VH-(D)-JH sequences were analyzed on the Internet by the Immunogenetics database (http://imgt.cines.fr: 8104),43 which identified the closest matching functional VH and JH segment. Those sequences that were not successfully matched were sent to BLAST (http://www.ncbi.nlm.nih.gov/BLAST/) on the Internet for possible matches to pseudogenes. The human VH locus as published by Matsuda et al4 was taken to be the main reference for comparison of sequences.

Statistical analysis

Standard statistical tests were carried out (χ2contingency tests, parametric and nonparametric t tests, and parametric and nonparametric correlation) by means of the statistical programs Graphpad Prism (Software Inc, San Diego, CA) and Statistical Product and Service Solutions (SPSS) 10.0 for Windows. Poisson regression statistics for analyzing rare frequencies were calculated on SAS, and nonlinear regression curve fitting was carried out on GraphPad Prism.

VH-(D)-JH rearrangement pattern in normal BM and normal PB

We used 6 normal adult BM samples and 6 normal adult PB samples for the amplification of VH-(D)-JHrearrangements by radiolabeled PCR followed by high-resolution polyacrylamide gel electrophoresis (PAGE). Amplified DNA products were found to be highly polyclonal, and evenly distributed DNA bands or ladders (average of 14 visible bands per ladder) were observed in both normal BM and PB (Figure 1), with each band within a ladder differing from the next by an estimated 1 base pair (bp). The total number of VH-(DH)-JH rearrangements were estimated to be equal to or greater than the total number of PCR bands observed, since each band can be expected to carry more than one clone (total estimate: greater than 472 for normal BM and greater than 525 for normal PB specimens). Bands were quantitated by densitometry, and data were pooled for every ladder to obtain the relative frequency of usage for each VH family (Table2; Figure2A-B). The intensity of bands for VH3 and VH4 families was always higher than those of other VH amplifications (particularly in the BM), accounting for 50% to 70% of all VH usage. VH1 followed with bands of intermediate to strong intensity (12% of all products), except for PB6 (less than 4%). In contrast, VH2, VH5, and VH6 bands were consistently weak (6%, 6%, and 2.6% of all products, respectively) and were often visualized only after prolonged exposure. In normal BM, the latter VH families always ranked in the following order: VH2 was greater than VH5, which was greater than VH6, and VH5 was sometimes slightly stronger in PB (PB1 and PB5), compared with VH2 and VH6. VH6 usage showed the faintest signals in all controls. The mean profiles are shown in Figure 2D. The overall ranking order of VH family usage for normal BM and PB was in broad agreement (VH3 was greater than VH4, which was greater than VH1, which was greater than VH2, which was greater than VH5, which was greater than VH6), with expected theoretical profiles calculated from germline segments (rearrangeable or functional) (Table1; Figure 2D) that have the same ranking order, except for VH1, which is expected to be stronger than VH4.

Fig. 1.

Typical PAGE fingerprints showing usage of VH families in VH-(D)-JHrearrangements.

(A) Full fingerprint of normal BM; film exposed for 24 hours. (B) Darkened sections from panel A for visualization of faint bands. (C) Film exposed for 10 days and showing blank control. (D) Adult ALL consisting of a major VH3-positive clonal population; 24 hours' exposure.

Fig. 1.

Typical PAGE fingerprints showing usage of VH families in VH-(D)-JHrearrangements.

(A) Full fingerprint of normal BM; film exposed for 24 hours. (B) Darkened sections from panel A for visualization of faint bands. (C) Film exposed for 10 days and showing blank control. (D) Adult ALL consisting of a major VH3-positive clonal population; 24 hours' exposure.

Close modal
Table 2.

VH segment usage in normal bone marrow and normal peripheral blood

VH familiesTotal VH
VH1/VH7VH2VH3VH4VH5VH6
Normal BM (6 donors)        
 Total reflected density of PCR ladders 575.3 210.2 2072.6 962.3 162.6 23.0 4005.9 
 Mean reflected density per donor 95.9 35.0 345.4 160.4 27.1 3.8 667.6 
 Mean relative frequencies (%) (14.4) (5.2) (51.7) (24) (4.1) (0.6)  
 SD (CV %) 51 (53) 24 (68) 22 (6) 29 (18) 17 (61) 3 (78)  
 Total no. PCR-amplified bands 90 60 126 116 60 20 472  
Normal PB (6 donors)        
 Total reflected density of PCR ladders 980.8 550.7 3336.1 2501.0 644.0 390.8 8403.4 
 Mean reflected density per donor 163.5 91.8 556.0 416.8 107.3 65.1 1400.6 
 Mean relative frequencies (%) (11.7) (6.6) (39.7) (29.8) (7.7) (4.7)  
 SD (CV %) 59 (36) 38 (41) 247 (44) 197 (47) 41 (38) 48 (74)  
 Total no. PCR-amplified bands 85 60 137 129 69 45 525 
VH familiesTotal VH
VH1/VH7VH2VH3VH4VH5VH6
Normal BM (6 donors)        
 Total reflected density of PCR ladders 575.3 210.2 2072.6 962.3 162.6 23.0 4005.9 
 Mean reflected density per donor 95.9 35.0 345.4 160.4 27.1 3.8 667.6 
 Mean relative frequencies (%) (14.4) (5.2) (51.7) (24) (4.1) (0.6)  
 SD (CV %) 51 (53) 24 (68) 22 (6) 29 (18) 17 (61) 3 (78)  
 Total no. PCR-amplified bands 90 60 126 116 60 20 472  
Normal PB (6 donors)        
 Total reflected density of PCR ladders 980.8 550.7 3336.1 2501.0 644.0 390.8 8403.4 
 Mean reflected density per donor 163.5 91.8 556.0 416.8 107.3 65.1 1400.6 
 Mean relative frequencies (%) (11.7) (6.6) (39.7) (29.8) (7.7) (4.7)  
 SD (CV %) 59 (36) 38 (41) 247 (44) 197 (47) 41 (38) 48 (74)  
 Total no. PCR-amplified bands 85 60 137 129 69 45 525 

BM indicates bone marrow; PCR, polymerase chain reaction; CV, coefficient of variation; PB, peripheral blood.

Fig. 2.

VH family usage profiles.

(A) Six normal adult BM samples. (B) Six normal adult PB samples. (C) Adult B-lineage ALL and other lymphoid malignancies (total alleles analyzed in brackets). (D) Expected usage (germline segments in brackets) and mean usage in normal BM and PB (estimated minimum number of clones in brackets).

Fig. 2.

VH family usage profiles.

(A) Six normal adult BM samples. (B) Six normal adult PB samples. (C) Adult B-lineage ALL and other lymphoid malignancies (total alleles analyzed in brackets). (D) Expected usage (germline segments in brackets) and mean usage in normal BM and PB (estimated minimum number of clones in brackets).

Close modal

To compare VH family usage profiles with expected theoretical profiles, the former were expressed as a ratio relative to the latter, with ratios near to 1 indicating similarity (Figure3A-B). Normal BM had smaller differences from germline VH (rearrangeable or functional) for VH families VH1 through VH5, with differences not exceeding 2.2-fold in either direction.VH6 usage was 3- to 4-fold lower than expected although original values for actual and expected usage were low (less than 2.5%). Normal PB matched germline VH(functional) well, with the largest deviation from the expected occurring at VH5 (3.2-fold) although all original values were small (less than 5%). Normal BM and normal PB were also compared with each other, and profiles were found to be similar, with the largest deviations occurring at VH6 (BM samples were 8.3-fold lower) although again all original values were low at less than 5%.

Fig. 3.

Relative VH family usage profiles (ratios).

Log-scale used throughout. (A) Mean normal BM relative to germline VH (rearrangeable), germline VH (functional), or mean normal PB. (B) Mean normal PB relative to germline VH (functional). (C) Adult B-lineage ALL relative to mean normal BM or germline VH (rearrangeable). (D) Adult cALL relative to mean normal BM or germline VH (rearrangeable). (E) Adult pre-B ALL relative to mean normal BM or germline VH (rearrangeable). (F) Childhood B-lineage ALL relative to mean normal BM or germline VH (rearrangeable). (G) B-cell lymphoma relative to mean normal PB and germline VH(functional). (H) CLL relative to mean normal PB and germline VH (functional). ▭, VH1;, VH2;, VH3;, VH4;, VH5;, VH6.

Fig. 3.

Relative VH family usage profiles (ratios).

Log-scale used throughout. (A) Mean normal BM relative to germline VH (rearrangeable), germline VH (functional), or mean normal PB. (B) Mean normal PB relative to germline VH (functional). (C) Adult B-lineage ALL relative to mean normal BM or germline VH (rearrangeable). (D) Adult cALL relative to mean normal BM or germline VH (rearrangeable). (E) Adult pre-B ALL relative to mean normal BM or germline VH (rearrangeable). (F) Childhood B-lineage ALL relative to mean normal BM or germline VH (rearrangeable). (G) B-cell lymphoma relative to mean normal PB and germline VH(functional). (H) CLL relative to mean normal PB and germline VH (functional). ▭, VH1;, VH2;, VH3;, VH4;, VH5;, VH6.

Close modal

Clonality of VH-(D)-JH rearrangements in adult B-lineage ALL

We assayed 159 adult patients with B-lineage ALL for the presence of VH-(D)-JH rearrangements as described above. We found 127 patients to have one or more discrete clonal VH-(D)-JH rearrangements (Figure 1D), unlike the normal BM ladders previously described. In 32 ALL patients (20%), no discrete bands were detected. A clonal pattern was highest in the subtypes L3 B ALL (4 of 4; 100%), followed by pre-B ALL (43 of 48; 91%), null ALL (12 of 14; 86%), and finally cALL (68 of 93; 74%).

Of the 127 clonal patients, 60 had a single clone (47.5%), 37 had 2 clones (29%), and 30 had 3 to 6 clones (23.5%), with an average of 1.9 clones per patient (excluding those with no clones). Among patients with 2 or more discrete bands, 58 out of 67 (86.5%) had signals of different intensities (greater than 4-fold differences by densitometry), suggestive of oligoclonality, as recently described.44 In the remaining 9 patients, 2 or more bands with similar densities were observed, and bi-allelic rearrangement could not be ruled out. Of the 245 total clones, 60 (24%) were monoclonal, 74 (30%) were biclonal, and 111 (45%) were from multiclonal cell populations. Each discrete band was taken to represent an independent clone of leukemia and was allocated to a VHfamily and scored as 1.

VH family usage in adult B-lineage ALL

As expected from the germline configuration and patterns seen in normal BM and PB, the largest number of clones identified were VH3 clones (88 of 245; 36%), followed by VH1 (50 of 245; 20.4%) and VH4 (46 of 245; 18.8%) (Table3). However, we observed that there were considerably more VH6 clones (41 of 245; 16.7%) than VH2 (13 of 245; 5.3%) and VH5 (7 of 245; 2.9%), contrary to a theoretical expectation of only 0.6% to 1.6%. Information on 102 alleles (in adults) and 91 alleles in children had been previously reported in a preliminary study.39 Except for VH6, the profile appears to be similar to the germline VH (rearrangable) profile.

Table 3.

VH segment usage in adult B-lineage acute lymphoblastic leukemia

No. patients with clonesNo. clones in VH familiesTotal
no. clones
VH1/VH7VH2VH3VH4VH5VH6
Adult B-lineage ALL 127 50 13 88 46 41 245 
 (%)  (20.4) (5.3) (36.0) (18.8) (2.9) (16.7)  
Subtypes         
 Null ALL 12 20 
  (%)  (20) (0) (20) (30) (10) (20)  
 Common ALL 68 33 53 23 18 135 
  (%)  (24.4) (3.7) (39.3) (17) (2.2) (13.3)  
 Pre-B ALL 43 12 28 15 18 82 
  (%)  (14.6) (8.5) (34.1) (18.3) (2.4) (22)  
 B ALL 
  (%)  (12.5) (12.5) (37.5) (25) (0) (12.5)  
No. patients with clonesNo. clones in VH familiesTotal
no. clones
VH1/VH7VH2VH3VH4VH5VH6
Adult B-lineage ALL 127 50 13 88 46 41 245 
 (%)  (20.4) (5.3) (36.0) (18.8) (2.9) (16.7)  
Subtypes         
 Null ALL 12 20 
  (%)  (20) (0) (20) (30) (10) (20)  
 Common ALL 68 33 53 23 18 135 
  (%)  (24.4) (3.7) (39.3) (17) (2.2) (13.3)  
 Pre-B ALL 43 12 28 15 18 82 
  (%)  (14.6) (8.5) (34.1) (18.3) (2.4) (22)  
 B ALL 
  (%)  (12.5) (12.5) (37.5) (25) (0) (12.5)  

ALL indicates acute lymphoblastic leukemia.

The largest immunophenotypic sub-group of adult B-lineage ALL in this study was represented by cALL (135 of 245; 55%). VH family usage for this group almost exactly mirrored the profile observed in ALL patients as a whole. VH family usage in pre-B ALL (82 of 245; 33%) showed a smaller proportional representation of VH1 (12 of 82; 14.6%) and an even greater bias toward VH6 usage (18 of 82; 22%). Comparable patterns were observed in null ALL (20 of 245; 8%) and L3 B ALL (8 of 245; 3%).

Statistical analyses were carried out (χ2 contingency test) comparing the actual frequencies of VH family usage in adult B-lineage ALL with expected frequencies. The expected frequencies were calculated by redistributing the total number of ALL clones in the same proportions as either (1) mean normal BM or (2) germline VH (rearrangeable). In both comparisons, adult B-lineage ALL was found to have a significantly different overall profile from what was expected (χ2 = 50,P < .0001; χ2 = 39,P < .0001, respectively), with deviation from the expected VH6 usage being the greatest contributory factor for both. The profile for adult B-lineage ALL was plotted as a ratio relative to mean normal BM or germline VH (rearrangeable) (Figure 3C). VH6 usage was higher than expected in both comparisons (29.2-fold and 9.2-fold, respectively). This observation remained true in the cALL and pre-B ALL sub-groups (Figure 3D-E), in which the latter showed greater deviation in VH6 usage from the expected (38.3-fold and 12.07-fold higher, respectively) than did the former (23.27-fold and 7.33-fold higher, respectively).

VH family usage in other lymphoid malignancies

For comparison, previous data on VH family usage in childhood B-lineage ALL (91 clones),39 B-cell lymphoma (36 clones), and CLL (56 clones) have been displayed in Table4 and Figure 2C. The childhood B-lineage ALL profile appears to be most similar to the adult pre-B ALL profile, with the exception that VH6, though overrepresented (10 of 91; 10%), is not as greatly elevated as in the adult ALL group. Both the lymphoma and CLL profiles closely resembled the germline VH functional profile (Figure 2D), with very low usage of VH6, in B-cell lymphoma (0 of 36; 0%), compared with an expected frequency of 2.4%, whereas VH6 usage in CLL was 3.6% (2 of 56). As with adult B-lineage ALL, all 3 profiles were plotted as ratios relative to the most appropriate expected profiles (Figure 3F-H). The childhood B-lineage ALL profile had higher-than-expected VH6 (19.17 relative to mean normal BM; 6.04 relative to germline rearrangeable VH) although, owing to lack of a large enough data set, statistical analysis could not be carried out. Both B-cell lymphoma and CLL had ratios close to 1 for all VH families.

Table 4.

VH gene segment usage in other lymphoid malignancies

No. patients with clonesNo. clones in VH familiesTotal
no. clones
VH1/VH7VH2VH3VH4VH5VH6
Childhood B-lineage ALL 63 13 10 39 15 10 91 
 (%)  (14.3) (11) (42.9) (16.5) (4.4) (11)  
B-cell lymphoma 36 19 36 
 (%)  (19.4) (2.8) (52.8) (16.7) (8.3) (0)  
CLL 56 11 26 12 56 
 (%)  (19.6) (5.4) (46.4) (21.4) (3.6) (3.6)  
No. patients with clonesNo. clones in VH familiesTotal
no. clones
VH1/VH7VH2VH3VH4VH5VH6
Childhood B-lineage ALL 63 13 10 39 15 10 91 
 (%)  (14.3) (11) (42.9) (16.5) (4.4) (11)  
B-cell lymphoma 36 19 36 
 (%)  (19.4) (2.8) (52.8) (16.7) (8.3) (0)  
CLL 56 11 26 12 56 
 (%)  (19.6) (5.4) (46.4) (21.4) (3.6) (3.6)  

ALL indicates acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia.

Sequence analysis of VH-(D)-JHrearrangements in adult B-lineage ALL

We further analyzed 77 of 254 adult B-lineage ALL clones by DNA sequencing (Table 5). The germline VH segment counterpart of the VHrearranged genes were identified in 65 clones. The remaining 12 could not be identified precisely, though they were clearly true VH-(D)-JH rearrangements (listed at bottom of Table 5). This was because the clone either (1) matched more than 3 known VH segments equally well, so no single segment could be assigned, or (2) did not match any of the published VHsegments well (less than 90% homology) and thus could have been a derivative of an unpublished polymorphic variable. Out of the 65 identified clones, 1 (clone 17) was allocated to the polymorphic variant VH (5-a), which has yet to be mapped, leaving 64 clones whose matching VH segments have been precisely mapped on the human VH locus. Five of these matched 2 to 3 different segments equally, and all possible matches have been listed. Three clones (323, 243c, 362b) matched polymorphic segments that occur in an as-yet-unsized proportion of the human population. Where this polymorphism occurs, the locus carries 5 extra VH segments between segments 3-30 and 4-31, widening the gap between the 2 by approximately 250 kilobases (kb). We found 2 clones that matched 2 rearrangeable pseudogenes (4-55 and 3-65).

Table 5.

Properties of sequenced VDJ rearrangements from 78 adult B-lineage acute lymphoblastic leukemia clones

Patient (clone)VH familyClosest matching
VHsegment5-150
Distance of VH from JH1 (kb)Closest matching
JHsegment
AgeSexImmunophenotypeKaryotypeWBC (log)Time to first CR5-151Clinical outcome5-152
57 VH6 -1 74.31 JH1 24 null ALL t(4;11) 2.75 standard CCR 
355 VH6 -1 74.31 JH2 40 null ALL t(4;11) 2.38 standard relapse 
406 VH6 -1 74.31 JH4 20 null ALL t(4;11) 2.58 standard CCR  
VH6 -1 74.31 JH5 17 CALL other  standard relapse 
110 VH6 -1 74.31 JH4 25 CALL normal 0.23 standard CCR 
181 VH6 -1 74.31 Unclear5-153 29 CALL normal 0.77 standard CCR 
243(a) VH6 -1 74.31 JH4 27 CALL other 0.32 standard relapse 
373 VH6 -1 74.31 JH4 48 CALL t(1;19)    
378(a) VH6 -1 74.31 JH5 20 CALL 9p abn   relapse  
80(a) VH6 -1 74.31 Unclear5-153 31 pre-B ALL  1.03 standard CCR  
192(a) VH6 -1 74.31 JH4 20 pre-B ALL t(4;11) 2.53 standard CCR 
192(b) VH6 -1 74.31 JH5 20 pre-B ALL t(4;11) 2.53 standard CCR 
223 VH6 -1 74.31 JH4 23 pre-B ALL 11q23 [non t(4;11)] 1.23 late relapse  
392 VH6 -1 74.31 JH4 39 pre-B ALL other  standard CCR  
263(a) VH1 -2 121.36 JH4 24 cALL  1.03 standard CCR 
321 VH1 -2 121.36 JH5 18 cALL HeH 1.34 standard relapse 
338 VH1 -2 121.36 JH4 27 cALL 9p abn 0.93 standard CCR  
378(b) VH1 -2 121.36 JH5 20 cALL 9p abn   relapse  
121 VH1 -3 139.94 JH4 19 cALL other 1.40 standard relapse 
1235-155 VH1 -35-155 139.94 JH6 16 pre-B ALL  0.36  relapse  
1265-155 VH1 -35-155 139.94 JH6 17 pre-B ALL 9p abn 1.42 standard relapse  
362(a) VH4 -4 146.80 JH5 29 cALL other 0.70 standard relapse 
26 VH4 -4 146.80 JH4 25 pre-B ALL t(12;21) 0.95 standard relapse 
410 VH4 -4 146.80 JH4 35 B ALL  2.11  CCR  
7(a) VH2 -5 162.83 JH6 31 pre-B ALL t(9;22) 1.96 late  
222(a) VH2 -5 162.83 JH4 40 pre-B ALL t(9;22) 2.05 standard CCR 
243(b) VH1 -8 207.77 JH5 27 cALL other 0.32 standard relapse 
263(b) VH1 -8 207.77 JH6 24 cALL  1.03 standard CCR 
374 VH3 -9 220.00 JH4 19 cALL    relapse 
72 VH3 -11 221.00 JH4 20 cALL    relapse 
204 VH3 -11 221.00 JH6 19 cALL HeH 0.52 standard CCR 
2835-155 VH3 -135-155 254.84 Unclear5-153 55 null ALL normal 0.70 standard CCR  
76 VH3 -13 254.84 JH6 21 cALL normal 1.58 standard CCR 
255(a) VH3 -13 254.84 JH4 16 cALL    relapse 
7(b) VH3 -13 254.84 JH6 31 pre-B ALL t(9;22) 1.96 late  
401 VH3 -13 254.84 JH5 49 pre-B ALL t(9;22)  standard relapse 
112 VH3 -23 393.91 JH5 22 pre-B ALL t(1;19) 1.59 late relapse 
177 VH3 -23 393.91 JH5 44 pre-B ALL 14q32 abn 0.85   
40 VH3 -30 459.71 JH6 19 cALL  1.59 standard  
198 VH3 -30 459.71 JH3 43 pre-B ALL t(9;22) 0.61 standard relapse 
323 VH4-30-4(poly) See text JH4 20 cALL other 1.74 standard CCR 
243(c) VH3-30/3-30-5(poly) See text JH1 27 cALL other 0.32 standard relapse 
389 VH4 -31 473.90 JH5 22 null ALL t(4;11) 2.30 standard relapse 
77(a) VH4 -31 473.90 JH6 24 pre-B ALL 6q del 1.19 standard CCR  
255(b) VH4 -39 546.31 JH5 16 cALL    relapse 
272 VH3 -43 594.90 JH4 28 cALL 6q del 1.65 standard CCR  
255(c) VH3 -48 662.52 JH5 16 cALL    relapse 
408 VH3 -53 717.67 JH6 18 cALL other 1.99 late relapse 
299(a) VH3 -53 717.67 Unclear5-153 18 pre-B ALL   standard CCR 
18 VH4-55(Ps) 730.82 JH4 16 pre-B ALL  1.36 standard CCR  
56 VH4 -61 763.82 JH5 16 cALL 14q32 abn 0.79 standard CCR  
376(a) VH3 -64 782.45 JH4 50 cALL t(9;22) 1.39 standard relapse 
327 VH3-65(Ps) 790.80 JH4 36 cALL  0.36 standard CCR 
289 VH1 -69 838.62 JH5 20 cALL  1.08 late CCR 
376(b) VH1 -69 838.62 JH4 50 cALL t(9;22) 1.39 standard relapse 
7(c) VH1 -69 838.62 JH6 31 pre-B ALL t(9;22) 1.96 late  
296 VH2 -70 847.52 Unclear5-153 40 pre-B ALL 12p abn 1.05 late CCR  
11 VH2 -70 847.52 JH4 19 B ALL  2.19 standard relapse  
134 VH3 -73 879.65 JH3 48 B ALL 14q32 abn 2.74 late relapse  
475-154 VH4 -45-154 146.80 JH5 26 cALL other 1.01 late CCR 
  4 -615-154 763.82         
1875-154 VH2 -55-154 162.83 JH4 24 cALL    relapse 
  2 -265-154 426.35         
  2 -705-154 847.52         
1955-154 VH4 -345-154 498.28 JH6 35 cALL t(9;22) 1.60 never  
  4 -395-154 546.31         
2625-154 VH4 -395-154 546.31 JH5 54 null ALL t(4;11) 2.34 late CCR  
  4 -595-154 751.94         
362(b)5-154 VH3 -305-154 459.71 JH4 29 cALL other 0.70 standard relapse 
  3-30-3 (poly)5-154 See text         
  3-30/3-30-5(poly)5-154 See text         
17 VH5-a(poly)# — JH6 16 pre-B ALL    relapse 
71 VH Unclear5-160 — JH4 16 cALL  0.63 standard CCR 
241 VH Unclear5-160 — Unclear5-154 16 cALL 12p abn 1.91 standard relapse 
248 VHUnclear5-160 — JH4 21 cALL HeH 0.40 standard CCR 
347(a) VHUnclear5-160 — JH5 27 cALL t(12;21) 1.60 standard relapse 
347(b) VHUnclear5-160 — JH4 27 cALL t(12;21) 1.60 standard relapse 
77(b) VHUnclear5-160 — JH6 24 pre-B ALL 6q del 1.19 standard CCR 
80(b) VHUnclear5-160 — JH5 31 pre-B ALL  1.03 standard CCR 
130 VH Unclear5-160 — JH5 30 pre-B ALL t(9;22) 1.89 late CCR 
149 VH Unclear5-160 — Unclear5-154 19 pre-B ALL 11q23 [non t(4;11)] 2.07 standard relapse 
222(b) VHUnclear5-160 — JH4 40 pre-B ALL t(9;22) 2.05 standard CCR 
299(b) VHUnclear5-160 — JH6 18 pre-B ALL   standard CCR 
375 VHUnclear5-160 — JH6 19 pre-B ALL HeH 0.48 standard relapse 
244 False†† False†† — False†† 50 null ALL t(4;11) 1.99 standard CCR 
Patient (clone)VH familyClosest matching
VHsegment5-150
Distance of VH from JH1 (kb)Closest matching
JHsegment
AgeSexImmunophenotypeKaryotypeWBC (log)Time to first CR5-151Clinical outcome5-152
57 VH6 -1 74.31 JH1 24 null ALL t(4;11) 2.75 standard CCR 
355 VH6 -1 74.31 JH2 40 null ALL t(4;11) 2.38 standard relapse 
406 VH6 -1 74.31 JH4 20 null ALL t(4;11) 2.58 standard CCR  
VH6 -1 74.31 JH5 17 CALL other  standard relapse 
110 VH6 -1 74.31 JH4 25 CALL normal 0.23 standard CCR 
181 VH6 -1 74.31 Unclear5-153 29 CALL normal 0.77 standard CCR 
243(a) VH6 -1 74.31 JH4 27 CALL other 0.32 standard relapse 
373 VH6 -1 74.31 JH4 48 CALL t(1;19)    
378(a) VH6 -1 74.31 JH5 20 CALL 9p abn   relapse  
80(a) VH6 -1 74.31 Unclear5-153 31 pre-B ALL  1.03 standard CCR  
192(a) VH6 -1 74.31 JH4 20 pre-B ALL t(4;11) 2.53 standard CCR 
192(b) VH6 -1 74.31 JH5 20 pre-B ALL t(4;11) 2.53 standard CCR 
223 VH6 -1 74.31 JH4 23 pre-B ALL 11q23 [non t(4;11)] 1.23 late relapse  
392 VH6 -1 74.31 JH4 39 pre-B ALL other  standard CCR  
263(a) VH1 -2 121.36 JH4 24 cALL  1.03 standard CCR 
321 VH1 -2 121.36 JH5 18 cALL HeH 1.34 standard relapse 
338 VH1 -2 121.36 JH4 27 cALL 9p abn 0.93 standard CCR  
378(b) VH1 -2 121.36 JH5 20 cALL 9p abn   relapse  
121 VH1 -3 139.94 JH4 19 cALL other 1.40 standard relapse 
1235-155 VH1 -35-155 139.94 JH6 16 pre-B ALL  0.36  relapse  
1265-155 VH1 -35-155 139.94 JH6 17 pre-B ALL 9p abn 1.42 standard relapse  
362(a) VH4 -4 146.80 JH5 29 cALL other 0.70 standard relapse 
26 VH4 -4 146.80 JH4 25 pre-B ALL t(12;21) 0.95 standard relapse 
410 VH4 -4 146.80 JH4 35 B ALL  2.11  CCR  
7(a) VH2 -5 162.83 JH6 31 pre-B ALL t(9;22) 1.96 late  
222(a) VH2 -5 162.83 JH4 40 pre-B ALL t(9;22) 2.05 standard CCR 
243(b) VH1 -8 207.77 JH5 27 cALL other 0.32 standard relapse 
263(b) VH1 -8 207.77 JH6 24 cALL  1.03 standard CCR 
374 VH3 -9 220.00 JH4 19 cALL    relapse 
72 VH3 -11 221.00 JH4 20 cALL    relapse 
204 VH3 -11 221.00 JH6 19 cALL HeH 0.52 standard CCR 
2835-155 VH3 -135-155 254.84 Unclear5-153 55 null ALL normal 0.70 standard CCR  
76 VH3 -13 254.84 JH6 21 cALL normal 1.58 standard CCR 
255(a) VH3 -13 254.84 JH4 16 cALL    relapse 
7(b) VH3 -13 254.84 JH6 31 pre-B ALL t(9;22) 1.96 late  
401 VH3 -13 254.84 JH5 49 pre-B ALL t(9;22)  standard relapse 
112 VH3 -23 393.91 JH5 22 pre-B ALL t(1;19) 1.59 late relapse 
177 VH3 -23 393.91 JH5 44 pre-B ALL 14q32 abn 0.85   
40 VH3 -30 459.71 JH6 19 cALL  1.59 standard  
198 VH3 -30 459.71 JH3 43 pre-B ALL t(9;22) 0.61 standard relapse 
323 VH4-30-4(poly) See text JH4 20 cALL other 1.74 standard CCR 
243(c) VH3-30/3-30-5(poly) See text JH1 27 cALL other 0.32 standard relapse 
389 VH4 -31 473.90 JH5 22 null ALL t(4;11) 2.30 standard relapse 
77(a) VH4 -31 473.90 JH6 24 pre-B ALL 6q del 1.19 standard CCR  
255(b) VH4 -39 546.31 JH5 16 cALL    relapse 
272 VH3 -43 594.90 JH4 28 cALL 6q del 1.65 standard CCR  
255(c) VH3 -48 662.52 JH5 16 cALL    relapse 
408 VH3 -53 717.67 JH6 18 cALL other 1.99 late relapse 
299(a) VH3 -53 717.67 Unclear5-153 18 pre-B ALL   standard CCR 
18 VH4-55(Ps) 730.82 JH4 16 pre-B ALL  1.36 standard CCR  
56 VH4 -61 763.82 JH5 16 cALL 14q32 abn 0.79 standard CCR  
376(a) VH3 -64 782.45 JH4 50 cALL t(9;22) 1.39 standard relapse 
327 VH3-65(Ps) 790.80 JH4 36 cALL  0.36 standard CCR 
289 VH1 -69 838.62 JH5 20 cALL  1.08 late CCR 
376(b) VH1 -69 838.62 JH4 50 cALL t(9;22) 1.39 standard relapse 
7(c) VH1 -69 838.62 JH6 31 pre-B ALL t(9;22) 1.96 late  
296 VH2 -70 847.52 Unclear5-153 40 pre-B ALL 12p abn 1.05 late CCR  
11 VH2 -70 847.52 JH4 19 B ALL  2.19 standard relapse  
134 VH3 -73 879.65 JH3 48 B ALL 14q32 abn 2.74 late relapse  
475-154 VH4 -45-154 146.80 JH5 26 cALL other 1.01 late CCR 
  4 -615-154 763.82         
1875-154 VH2 -55-154 162.83 JH4 24 cALL    relapse 
  2 -265-154 426.35         
  2 -705-154 847.52         
1955-154 VH4 -345-154 498.28 JH6 35 cALL t(9;22) 1.60 never  
  4 -395-154 546.31         
2625-154 VH4 -395-154 546.31 JH5 54 null ALL t(4;11) 2.34 late CCR  
  4 -595-154 751.94         
362(b)5-154 VH3 -305-154 459.71 JH4 29 cALL other 0.70 standard relapse 
  3-30-3 (poly)5-154 See text         
  3-30/3-30-5(poly)5-154 See text         
17 VH5-a(poly)# — JH6 16 pre-B ALL    relapse 
71 VH Unclear5-160 — JH4 16 cALL  0.63 standard CCR 
241 VH Unclear5-160 — Unclear5-154 16 cALL 12p abn 1.91 standard relapse 
248 VHUnclear5-160 — JH4 21 cALL HeH 0.40 standard CCR 
347(a) VHUnclear5-160 — JH5 27 cALL t(12;21) 1.60 standard relapse 
347(b) VHUnclear5-160 — JH4 27 cALL t(12;21) 1.60 standard relapse 
77(b) VHUnclear5-160 — JH6 24 pre-B ALL 6q del 1.19 standard CCR 
80(b) VHUnclear5-160 — JH5 31 pre-B ALL  1.03 standard CCR 
130 VH Unclear5-160 — JH5 30 pre-B ALL t(9;22) 1.89 late CCR 
149 VH Unclear5-160 — Unclear5-154 19 pre-B ALL 11q23 [non t(4;11)] 2.07 standard relapse 
222(b) VHUnclear5-160 — JH4 40 pre-B ALL t(9;22) 2.05 standard CCR 
299(b) VHUnclear5-160 — JH6 18 pre-B ALL   standard CCR 
375 VHUnclear5-160 — JH6 19 pre-B ALL HeH 0.48 standard relapse 
244 False†† False†† — False†† 50 null ALL t(4;11) 1.99 standard CCR 

ALL indicates acute lymphoblastic leukemia; cALL, common ALL.

F5-150

All named matches have less than 97% homology with no more than 3 mismatching base pairs, except those marked with ∥.

F5-151

Standard time to CR is up to 42 days.

F5-152

Patients followed for at least 24 months or up to first relapse.

F5-153

Clones were found to match more than 1 JH segment equally well; therefore, a JH segment was not assigned.

F5-155

These matches were relatively poor (90% to 95% homology) with between 8 and 10 mismatching base pairs.

F5-154

Clones were found to match 2 to 3 VH segments equally well; all possibilities are listed.

#This polymorphic VH segment has not been accurately mapped at present.

F5-160

Clones were found to match more than 3 VH segments equally well; therefore, a VH segment was not assigned.

JH segment usage

We successfully assigned known JH segments to 70 clones (Table 5; Figure 4). In 7 other clones, the rearrangement process resulted in the deletion of a sizable section of the JH, making it difficult to precisely identify the germline sequence. JH4 occurred most commonly (29 of 70; 41.4%), followed by JH5 (20 of 70; 28.6%) and then JH6 (16 of 70; 23.9%). JH1, JH2, and JH3 rearrangements were rare at between 1.4% and 2.9% (2 of 70; 1 of 70; 2 of 70, respectively).

Fig. 4.

JH gene segment usage in 70 sequenced adult B-lineage ALL clones.

The JH usage is expressed as the percentage of all alleles studied and is illustrated by vertical bars.

Fig. 4.

JH gene segment usage in 70 sequenced adult B-lineage ALL clones.

The JH usage is expressed as the percentage of all alleles studied and is illustrated by vertical bars.

Close modal

Positional analysis of VH gene usage in adult B-lineage ALL

Frequency of usage of specific germline VHsegments by adult B-lineage ALL (total, 64 clones) was scored (Figure5). Only segments capable of rearranging (including pseudogenes) were considered. These included VHgenes with intact RS and promoter sequences. Segments without these elements were never found rearranged and were therefore excluded from further analysis. Note that in addition to the 55 rearrangeable segments taken from Table 1, five polymorphic segments (not reported in Matsuda et al4) have also been included in Figure 5. Where a clone was assigned to 2 or 3 possible segments, each possibility was given a score of 0.5 or 0.33, accordingly. We observed that 29 out of 60 (48%) rearrangeable VH segments were used at least 0.33 times. Nonused VH segments were scattered across the locus, including a clump of 6 adjacent segments near the JH locus. The most JH-proximal segment(VH6) was overused (14 of 64; 22%) with a considerably higher frequency than the second most common segment (3-13; 5 of 64; 7.8%). Segments with a frequency of more than 2 tended to occur near to the JH locus, whereas those with frequencies of 2 or lower were more often found in the midsection and upstream.

Fig. 5.

VH gene segment usage in 63 sequenced adult B-lineage ALL clones.

Only rearrangeable segments have been shown. Asterisk indicates that clone matched 2 to 3 segments in total, and each segment has been given a score of 0.33 or 0.5, accordingly.

Fig. 5.

VH gene segment usage in 63 sequenced adult B-lineage ALL clones.

Only rearrangeable segments have been shown. Asterisk indicates that clone matched 2 to 3 segments in total, and each segment has been given a score of 0.33 or 0.5, accordingly.

Close modal

We estimated that if each segment had an equal chance of being selected for rearrangement, the expected frequency would be around 1 per segment, which differs from our observation. The hypothesis that the frequency of usage of any VH segment is a function of its distance from the JH locus was tested and confirmed by Poisson regression analysis and found to be correct (P = .0009; Figure 6A). This finding remains true, even when the extremeVH6 data were excluded from the calculation (P = .0017; Figure 6B). For simplicity, polymorphic segments were excluded from these calculations, and noninteger frequencies were truncated to the nearest integer (total frequencies equal 58 or 44 without VH6).

Fig. 6.

Comparison of expected and actual VH gene segment usage in sequenced adult B-lineage ALL clones in relation to distance upstream from JH locus.

(A) All clones. (B) Excluding VH6 clones. ●, actual frequency; ○, expected frequency.

Fig. 6.

Comparison of expected and actual VH gene segment usage in sequenced adult B-lineage ALL clones in relation to distance upstream from JH locus.

(A) All clones. (B) Excluding VH6 clones. ●, actual frequency; ○, expected frequency.

Close modal

We attempted to fit a simple model of nonlinear regression to our data, using the principles of one-phase exponential decay (used for defining radioactive decay over time). This model is defined by the equation below and was found to represent our data reasonably well, with and without VH6 data (Figure7A-B). The equation for the curve is Y = span · e−K·X + plateau, where span is the highest possible frequency, plateau is the lowest frequency,K is a unique constant, and the half-life equals 0.69/K. For the curve shown in Figure 7B, the span equals 21, the plateau equals 0.5, K equals 0.0154, and the frequency decreased by half (half-life) every 45 kb upstream from the first segment. Thus, it has been shown that the relationship between frequency of VH gene segment usage and distance from JH locus can be mathematically defined.

Fig. 7.

Nonlinear regression model of VH usage across distance upstream of JH1, using the principles of one-phase exponential decay.

(A) Frequency of VH gene usage including the VH6. (B) Frequency of VH gene usage excluding the VH6 gene.

Fig. 7.

Nonlinear regression model of VH usage across distance upstream of JH1, using the principles of one-phase exponential decay.

(A) Frequency of VH gene usage including the VH6. (B) Frequency of VH gene usage excluding the VH6 gene.

Close modal

Mature B-cell populations

Our study analyzed VH gene segment usage during VH-(D)-JH rearrangement in B cells from adult and childhood B-lineage ALL populations. We also assessed the baseline patterns in normal BM and normal PB B-cell populations, which showed no difference from the predicted profiles. The patterns in chronic lymphoid malignancies (in CLL) and lymphomas were also assessed and found to conform to profiles derived from mature post–antigen-stimulation B-cell profiles.16-21,37 45-48 

By contrast, adult B-lineage ALL clones, taken as models of progenitors and precursors of B cells, showed a statistically significant deviation from the expected pattern, with overrepresentation ofVH6 rearrangements and use of JH-proximal segments. We showed that the relationship between frequency of usage and location on VH locus can be mathematically defined by one-phase exponential decay whereby the frequency of usage halves with every 45-kb distance away from JH proximity. It could be argued that the unexpected usage of individual VH genes are a result of the leukemic process' driving an unnatural pattern of VH rearrangement, rather than a reflection of truly normal preimmune B-cell events. We believe that our data reflect what could be a normal pattern of IGH rearrangements in pre–antigen-stimulation B cells, as the data do not differ from those in studies of fetal human and mouse B cells. The difference observed between BM or PB and the ALL group reflects a biological rather than a disease-related difference, as we first suggested in a preliminary study.49 Comparing our results with previous reports, we did not find overuse of VH5 (previously described as VH251) in ALL50 or VH (4-34), VH(4-39), VH (4-59), VH (3-23), and VH (3-30) in fetal bone marrow.28 

The VH6 gene

The highly polymorphic human VH region is thought to have arisen prior to racial divergence and has been stable for at least 30 000 years.51 However, VH6 is unusual in being the sole member of its family with no polymorphic variables in different individuals52 and racial groups.51 Lack of genetic polymorphism in the 30-kb area around the VH6 segment is in sharp contrast to the expected occurrence of a restriction fragment length polymorphism every 100 to 300 bp.53 A relative lack of repetitive elements in the same area is also unusual.4,54 It has been suggested that VH6 is protected from mutations by strong selection pressure to maintain this area intact.51 Compelling studies of the nature of theVH6 promoter have revealed that it has many unique features not shared by the other VH segment promoters. Promoters of VH genes contain one consistent transcription-factor–binding site, in addition to the TATA box. This octamer motif, with a consensus sequence ATGCAAAT, is found approximately 70 bases upstream of the transcription initiation site. The motif is perfectly conserved in all but 3 of the 42 functional VH segments (octamers for the segments 3-20, 3-53, andVH6 have 1- to 2-bp variations on the consensus). The presence of an octamer is an absolute requirement for tissue-specific transcription of VH segments in vivo and in vitro,55-57 and a single base change prevents the binding of the Octamer-2 (a B-lineage–specific transcription factor).58 Sun and Kitchingman59,60 have shown that the imperfect VH6 octamer, with a single base-pair change (AgGCAAAT), lacks B-cell specificity and transcribes in an enhancer-independent fashion, has bidirectional transcriptional capabilities, and has greater transcriptional strength. Furthermore, non–B-cell silencer activity, as found in one of the VH2 promoters, was not found in VH6. These data suggest that the VH6 promoter is under a different transcriptional control compared with other VH promoters. VH6 promoter is often the first VH promoter activated during ontogeny and is also overrepresented in artificially activated resting small B cells.19 61 

Our study describes, with statistical relevance, the overusage of theVH6 segment during VH-(D)-JH rearrangement, which we had previously noted in ALL.39 Our work supports the idea thatVH6 has special properties, such as marking the cells ready to undergo true semi-random rearrangement. Of note, there is a non-VH gene (KIAA0125) near the 3′ side ofVH64 in the reverse orientation toVH6, which has an extremely short coding region but extensive 5′ and 3′ untranslated regions and shows lymphoid-restricted expression,62 with as-yet-unidentified function.

VH pseudogenes

We were interested in analyzing how often pseudogenes, which retained both their abilities to transcribe and rearrange with intact promoters and RS sequences (13 of 81; 16%) but failed to yield productive proteins, were used. Although pseudogenes make up a sizable proportion of the total rearrangeable segments (13 of 55; 24%), only 2 (3%) of such pseudogenes were found rearranged in our study. From an examination of their locations in the VH locus (Figures 5and 6), it can be seen that the majority of the rearrangeable pseudogenes (9 of 13; 69%) lie at 500 kb or more from JH1. This area corresponds to the plateau of the exponential-decay usage curve; therefore, a low rate of usage can be expected. Even so, pseudogene usage appeared to be lower than expected. Although all VH segments with intact promoters and RS sequences can rearrange, restriction selection of wasteful VH-(D)-JH recombinations may occur.

JH segment usage

We found that JH4, JH5, and JH6 were greatly overrepresented, in keeping with most previous reports in childhood ALL63-65 and adult PB,66 with the exception that they all report a predominance order of JH4 being greater than or equal to JH6, which is greater thanJH5, whereas we find an order of JH4 greater than JH5, which is greater thanJH6. Preimmune cells from fetal liver use JH3 and JH4, with littleJH5 and very little JH6and JH1.29,30 Cuisiner and colleagues24 revealed that although the overall order of preference in fetal liver wasJH3 = JH4, which is greater than(JH1 = JH2 = JH5 = JH6),on close inspection, JH6 usage, which was otherwise rare, strongly associated with VH6usage. On the contrary, none of the JH6-positive clones in adult B-lineage ALL were VH6 positive (Table 5). This is good evidence that the increasedVH6 usage observed in adult preimmune cells is unrelated to that seen in fetal B cells and that separate mechanisms give rise to the observed repertoires.

In summary, we have shown that the profiles of VH gene family usage in normal BM and PB are in broad agreement with theoretical values calculated under the assumption that all rearrangeable VH segments have an equal probability of being selected. Furthermore, B-lineage cells from clonally expanded populations from B-cell lymphoma and CLL conform to this pattern. However, clones from early B-cell progenitors of precursor populations (from ALLs) do not conform to this pattern, so the assumption made does not hold true. Detailed analyses have revealed that rate of VH usage is proportional to proximity to the JHlocus. It is plausible that most B cells first undergo rearrangement preferentially using JH-proximal VH, and that further rounds of VH recombining with (D)-JHoccur later on, with the effect of normalizing the observed VH repertoire. The final repertoire would appear unbiased with all VH segments represented in their correct proportions, excluding a role for this phenomenon in leukemogenesis.

We thank Richard Morris (Population Sciences and Epidemiology, Royal Free Hospital, London, United Kingdom) for his kind help with statistical analyses; Julie Burrett (Clinical Trial Service Unit, Oxford, United Kingdom) for clinical information on patients; Dr Paul Travers (Anthony Nolan Centre, London, United Kingdom) and Professor Lucio Luzzatto (Istituto Scientifico Tumori, Genoa, Italy) for helpful discussions; and all of the United Kingdom clinicians involved in the Adult UKALL XII study who supplied bone marrow samples for this study.

Supported by the Kay Kendall Leukaemia Fund and the Leukaemia Research Fund, United Kingdom.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Tonegawa
 
S
Somatic generation of antibody diversity.
Nature.
302
1983
575
581
2
Alt
 
FW
Blackwell
 
TK
Yancopoulos
 
GD
Development of the primary antibody repertoire.
Science.
238
1987
1079
1087
3
Cook
 
GP
Tomlinson
 
IM
The human immunoglobulin VH repertoire.
Immunol Today.
16
1995
237
242
4
Matsuda
 
F
Ishii
 
K
Bourvagnet
 
P
et al
The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus.
J Exp Med.
188
1998
2151
2162
5
Ravetch
 
JV
Siebenlist
 
U
Korsmeyer
 
S
Waldmann
 
T
Leder
 
P
Structure of the immunoglobulin μ locus: characterization of embryonic and rearranged J and D genes.
Cell.
27
1981
583
591
6
Tomlinson
 
IM
Walter
 
G
Marks
 
JD
Llewelyn
 
MB
Winter
 
G
The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops.
J Mol Biol.
227
1992
776
798
7
Akira
 
S
Okazaki
 
K
Sakano
 
H
Two pairs of recombination signals are sufficient to cause immunoglobulin V-(D)-J joining.
Science.
238
1987
1134
1138
8
Blackwell
 
T
Moore
 
M
Yancopoulos
 
G
et al
Recombination between immunoglobulin variable region gene segments is enhanced by transcription.
Nature.
324
1986
585
587
9
Goldman
 
JP
Spencer
 
DM
Raulet
 
DH
Ordered rearrangement of variable region genes of the T cell receptor gamma locus correlates with transcription of the unrearranged genes.
J Exp Med.
177
1993
729
739
10
Koenig
 
N
Malone
 
B
Hoch
 
S
Schwaber
 
J
Transcription of germline VH elements by normal human fetal liver.
Mol Immunol.
34
1997
333
341
11
Sleckman
 
BP
Gorman
 
JR
Alt
 
FW
Accessibility control of antigen receptor variable region gene assembly: role of cis-acting elements.
Annu Rev Immunol.
14
1996
459
481
12
Yu
 
CCK
Larijani
 
M
Miljanic
 
IN
Wu
 
GE
Differential usage of VH gene segments is mediated by cis elements.
J Immunol.
161
1998
3444
3454
13
Webb
 
CF
Dou
 
SS
Buchanan
 
KL
Resta
 
R
Smithson
 
G
Smith
 
EA
Reassessment of germline heavy chain transcripts from two murine V-H families.
Mol Immunol.
34
1997
743
750
14
Angelin-Duclos
 
C
Calame
 
K
Evidence of immunoglobulin VH-DJ recombination does not require germ line transcription of the recombining variable gene segment.
Mol Cell Biol.
18
1998
6253
6264
15
Love
 
VA
Lugo
 
G
Merz
 
D
Feeney
 
AJ
Individual V(H) promoters vary in strength, but the frequency of rearrangement of those V(H) genes does not correlate with the promoter strength nor enhancer-independence.
Mol Immunol.
37
2000
29
39
16
Cuisiner
 
A-M
Guigou
 
V
Boubli
 
L
Fougereau
 
M
Tonnelle
 
C
Preferential expression of VH5 and VH6 immunoglobulin genes in early human B-cell ontogeny.
Scand J Immunol.
30
1989
493
497
17
Berman
 
JE
Nickerson
 
KG
Pollock
 
RR
et al
VH gene usage in humans: biased usage of the VH6 gene in immature B lymphoid cells.
Eur J Immunol.
21
1991
1311
1314
18
Brezinschek
 
HP
Brezinschek
 
RI
Lipsky
 
PE
Analysis of the heavy chain repertoire of human peripheral B cells using single cell polymerase chain reaction.
J Immunol.
155
1995
190
202
19
Davidkova
 
G
Petterson
 
S
Holmberg
 
D
Lundvist
 
I
Selective usage of VH genes in adult human B lymphocyte repertoires.
Scand J Immunol.
45
1997
62
73
20
Kantor
 
AB
Merill
 
CE
Herzenberg
 
LA
Hillson
 
JL
The unbiased analysis of V(H)-D-J(H) sequences from B-1a, B-1b, and conventional B cells.
J Immunol.
158
1997
1175
1186
21
Wilson
 
PC
Wilson
 
K
Liu
 
YJ
Banchereau
 
J
Pascual
 
V
Capra
 
JD
Receptor revision of immunoglobulin heavy chain variable region genes in normal human B lymphocytes.
J Exp Med.
191
2000
1881
1894
22
Jeong
 
HD
Teale
 
JM
Contribution of the CD5+ B cell to D-proximal VH family expression early in ontogeny.
J Immunol.
145
1990
2725
2729
23
Malynn
 
BA
Yancopoulos
 
GD
Barth
 
JE
Bona
 
CA
Alt
 
FW
Biased expression of JH-proximal VH genes occurs in the newly generated repertoire of neonatal and adult mice.
J Exp Med.
171
1990
843
859
24
Cuisiner
 
A-M
Gauthier
 
L
Boubli
 
L
Fougereau
 
M
Tonelle
 
C
Mechanisms that generate human immunoglobulin diversity operate from the 8th week of gestation in fetal liver.
Eur J Immunol.
23
1993
110
118
25
Ravichandran
 
KS
Osborne
 
BA
Goldsby
 
RA
Quantitative analysis of the B cell repertoire by limiting dilution analysis and fluorescent in-situ hybridisation.
Cell Immunol.
154
1994
306
327
26
Marshall
 
AJ
Wu
 
GE
Paige
 
CJ
Frequency of VH81x usage during B cell development: initial decline in usage is independent of Ig heavy chain cell surface expression.
J Immunol.
156
1996
2077
2084
27
Marshall
 
AJ
Paige
 
CJ
Wu
 
GE
V(H) repertoire maturation during B cell development in vitro: differential selection of Ig heavy chains by fetal and adult B cell progenitors.
J Immunol.
158
1997
4282
4291
28
Rao
 
SP
Riggs
 
JM
Friedman
 
DF
Scully
 
MS
LeBien
 
TW
Silberstein
 
LE
Biased VH gene usage in early lineage human B cells: evidence for preferential Ig gene rearrangement in the absence of selection.
J Immunol.
163
1999
2732
2740
29
Schroeder
 
HW
Hillson
 
JL
Perlmutter
 
RM
Early restriction of the human antibody repertoire.
Science.
238
1987
791
793
30
Schroeder
 
HW
Wang
 
JY
Preferential utilization of conserved immunoglobulin heavy chain variable gene segments during human fetal life.
Proc Natl Acad Sci U S A.
87
1990
6146
6150
31
Raaphorst
 
FM
Langlois van den Bergh
 
RL
Waaijer
 
JL
Vossen
 
JM
van Tol
 
MJ
Expression of the human immunoglobulin heavy chain VH6 gene element by fetal B lymphocytes.
Scand J Immunol.
46
1997
292
297
32
ten Boekel
 
E
Melchers
 
F
Rolink
 
AG
Changes in the V(H) gene repertoire of developing precursor B lymphocytes in mouse bone marrow mediated by the pre-B cell receptor.
Immunity.
7
1997
357
368
33
Storek
 
J
King
 
L
Ferrara
 
S
Marcelo
 
D
Saxon
 
A
Braun
 
J
The abundance of a restricted fetal B cell repertoire in marrow transplant recipients.
Bone Marrow Transplant.
14
1994
783
790
34
Gokmen
 
E
Raaphorst
 
FM
Boldt
 
DH
Teale
 
JM
Ig heavy chain complementarity determining regions (H CDR3s) after stem cell transplantation do not resemble the developing human fetal H CDR3s in size distribution and Ig gene utilization.
Blood.
8
1998
2802
2814
35
Näsman-Björk
 
I
Lundkvist
 
I
Oligoclonal dominance of immunoglobulin VH3 rearrangements following allogeneic bone marrow transplantation.
Bone Marrow Transplant.
21
1998
1223
1230
36
Näsman-Björk
 
I
Lundkvist
 
I
Evidence for oligoclonal diversification of the V(H)6-containing immunoglobulin repertoire during reconstitution after bone marrow transplantation.
Blood.
87
1996
2795
2804
37
Deane
 
M
Norton
 
JD
Immunoglobulin heavy chain variable region family usage is independent of tumor cell phenotype in human B lineage leukaemias.
Eur J Immunol.
20
1990
2209
2217
38
Maloum
 
K
Magnac
 
C
Pritsh
 
O
Binet
 
JL
Merleberal
 
H
Dighiero
 
G
Skewed rearrangement of the VH4–21 gene during pre-B acute lymphoblastic leukaemia.
Leuk Lymph.
17
1995
435
441
39
Coyle
 
LA
Papaioannou
 
M
Yaxley
 
JC
et al
Molecular analysis of the leukaemic B-cell in adult and childhood acute lymphoblastic leukaemia.
Br J Haematol.
94
1996
685
693
40
Bennett
 
JM
Catovsky
 
D
Daniel
 
MT
et al
Proposals for the classification of the acute leukemias. French-American-British (FAB) co-operative group.
Br J Haematol.
33
1976
451
458
41
Chim
 
JCS
Coyle
 
LA
Yaxley
 
JC
et al
The use of IgH fingerprinting and ASO-dependent PCR for the investigation of residual disease (MRD) in ALL.
Br J Haematol.
92
1996
104
115
42
Campbell
 
MJ
Zelenetz
 
AD
Levy
 
S
Levy
 
R
Use of family-specific leader region primers for PCR amplification of the human heavy-chain variable region gene repertoire.
Mol Immunol.
29
1992
193
203
43
LeFranc
 
M-P
Guidicelli
 
V
Ginestoux
 
C
et al
IMTG, the international ImMunoGeneTics database.
Nucleic Acid Res.
27
1999
209
212
44
Papaioannou
 
M
Coyle
 
LA
Yaxley
 
JC
Hoffbrand
 
AV
Foroni
 
L
Oligoclonality in acute lymphoblastic leukaemia [abstract].
Br J Haematol.
97(suppl 1)
1997
200a
45
Sakai
 
A
Marti
 
GE
Caporaso
 
N
et al
Analysis of expressed immunoglobulin heavy chain genes in familial B-CLL.
Blood.
95
2000
1413
1419
46
Chapman
 
CJ
Wright
 
D
Stevenson
 
FK
Insight into Burkitt's lymphoma from immunoglobulin variable region gene analysis.
Leuk Lymph.
30
1998
257
267
47
Tamaru
 
J
Hummel
 
M
Marafioti
 
T
et al
Burkitt's lymphomas express VH genes with a moderate number of antigen-selected somatic mutations.
Am J Pathol.
147
1995
1398
1407
48
Nakamura
 
N
Hashimoto
 
Y
Kuse
 
T
et al
Analysis of the immunoglobulin heavy chain gene variable regions of CD5-positive diffuse large B-cell lymphoma.
Lab Invest.
79
1999
925
933
49
Foroni
 
L
Catovsky
 
D
Rabbitts
 
TH
Luzzatto
 
L
DNA rearrangements of immunoglobulin genes correlate with phenotypic markers in B-cell malignancies.
Mol Biol Med.
2
1984
63
79
50
Deane
 
M
Norton
 
JD
Detection of immunoglobulin gene rearrangement in B lymphoid malignancies by polymerase chain reaction gene amplification.
Br J Haematol.
74
1990
251
256
51
Walter
 
MA
Cox
 
DW
Nonuniform linkage disequilibrium within a 1,500-kb region of the human immunoglobulin heavy-chain complex.
Am J Hum Genet.
49
1991
917
931
52
Sanz
 
I
Kelly
 
P
Williams
 
C
Scholl
 
S
Tucker
 
P
Capri
 
JD
The smaller human VH families display remarkably little polymorphism.
EMBO J.
8
1989
3741
3748
53
Cooper
 
DN
Smith
 
BA
Cooke
 
HJ
Niemann
 
S
Schmidtke
 
J
An estimate of unique DNA sequence heterozygosity in the human genome.
Hum Genet.
69
1985
201
205
54
Schroeder
 
HW
Walter
 
MA
Hofker
 
MH
et al
Physical linkage of a human immunoglobulin heavy chain variable region gene segment to diversity and joining region elements.
Proc Natl Acad Sci U S A.
85
1988
8196
8200
55
Grosschedl
 
R
Baltimore
 
D
Cell-type specificity of immunoglobulin gene-expression is regulated by at least 3 DNA-sequence elements.
Cell.
41
1985
885
897
56
Eaton
 
S
Calame
 
K
Multiple DNA-sequence elements are necessary for the function of an immunoglobulin heavy-chain promoter.
Proc Natl Acad Sci U S A.
84
1987
7634
7638
57
LeBowitz
 
JH
Kobayashi
 
T
Staudt
 
L
Baltimore
 
D
Sharpe
 
PA
Octamer-binding proteins from B-cells or HeLa cells stimulate transcription of the immunoglobulin heavy-chain promoter in vitro.
Genes Dev.
2
1988
1227
1237
58
Staudt
 
LM
Singh
 
H
Sen
 
R
et al
A lymphoid-specific protein binding to the octamer motif of immunoglobulin genes.
Nature.
323
1986
640
643
59
Sun
 
Z
Kitchingman
 
GR
Analysis of the imperfect octamer-containing human immunoglobulin VH6 gene promoter.
Nucleic Acids Res.
22
1994
850
860
60
Sun
 
Z
Kitchingman
 
GR
Bidirectional transcription from the human immunoglobulin VH6 gene promoter.
Nucleic Acids Res.
22
1994
861
868
61
van Dijk-Hard
 
I
Feld
 
S
Holmberg
 
B
Lundkvist
 
I
Increased utilization of the VH6 gene family in patients with autoimmune idiopathic thrombocytopenic purpura.
J Autoimmun.
12
1999
57
63
62
Nagase
 
T
Seki
 
N
Tanaka
 
A
Ishikawa
 
A
Nomura
 
A
Prediction of the coding sequences of unidentified human genes, IV: the coding sequences of 40 new genes (KIAA0121-KIAA0160) deduced by analysis of cDNA clones from human cell line KG-1.
DNA Res.
2
1995
167
174
63
Wasserman
 
R
Ito
 
Y
Galili
 
N
et al
The pattern of joining (JH) gene usage in the human IgH chain is established predominantly at the B precursor cell stage.
J Immunol.
149
1992
511
516
64
Wasserman
 
R
Galili
 
N
Ito
 
Y
Reichard
 
BA
Shane
 
S
Rovera
 
G
Predominance of fetal type DJH joining in young children with B precursor lymphoblastic leukemia as evidence for an in utero transforming event.
J Exp Med.
176
1992
1577
1581
65
Steenbergen
 
EJ
Verhagen
 
OJHM
van Leeuwen
 
EF
et al
B precursor acute lymphoblastic leukemia third complementarity-determining regions predominantly represent an unbiased recombination repertoire: leukemic transformation occurs in fetal life.
Eur J Immunol.
24
1994
900
908
66
Yamada
 
M
Wasserman
 
R
Reichard
 
BA
Shane
 
S
Caton
 
AJ
Rovera
 
G
Preferential utilization of specific immunoglobulin heavy chain diversity and joining segments in adult peripheral blood B lymphocytes.
J Exp Med.
173
1991
395
407

Author notes

Letizia Foroni, Department of Haematology, Royal Free and University College of London (Royal Free Campus), Pond St, London NW3 2QG, United Kingdom; e-mail: letizia@rfc.ucl.ac.uk.

Sign in via your Institution